IL-8 Antibody Active in Tumors After PD-1/L1 Blockade MedPage Today, 13 Nov 2020 Meeting Coverage > SITC Clinical benefit in more than a third of patients with anti-IL-8/nivolumab combo by Charles Bankhead…